Literature DB >> 6138236

Disposition of hexobarbital enantiomers in the rat.

M van der Graaff, N P Vermeulen, R P Joeres, D D Breimer.   

Abstract

The enantiomers of hexobarbital (HB), designated as (+)-HB and (-)-HB, were administered orally to separate groups of rats. Blood concentration-time curves of the parent compounds and the metabolites 3'-hydroxyhexobarbital (OH-HB) and 3'-ketohexobarbital (K-HB) were determined, as well as the cumulative urinary excretion of unconjugated OH-HB, K-HB, and 1,5-dimethylbarbituric acid (DMBA). The t1/2,(+)-HB was 13.4 +/- 0.8 min, and the t1/2,(-)-HB was slightly longer, 16.7 +/- 0.6 min (mean +/- SEM, N = 6). The intrinsic clearance values, CLint,(+)-HB and CLint,(-)-HB, were 2947 +/- 358 and 411 +/- 65 ml min-1 kg-1, respectively. The extraction ratios (E) were 0.94 for (+)-HB and 0.68 for (-)-HB. The t1/2,OH-(+)-HB and t1/2,OH-(-)-HB as calculated from blood data, were nearly the same: 20.0 +/- 2.6 and 22.2 +/- 1.5 min, respectively. Such data could not be established for the K-HB metabolites, since the curves exhibited no clear elimination phase. DMBA was undetectable in blood. The cumulative excretion of the measured metabolites in 24-hr urine was 44.0 +/- 1.8% for (+)-HB and 78.9 +/- 2.9% for (-)-HB, which was predominantly due to a substantial difference in the percentage of K-HB excreted. It is concluded that, to apply HB as a model substrate to assess oxidative enzyme activity, the use of only (-)-HB should be preferred to (+)-HB or (+/-)-HB because of a lower intrinsic clearance and a more complete recovery of oxidized metabolites in urine.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6138236

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  6 in total

Review 1.  Electroencephalogram effect measures and relationships between pharmacokinetics and pharmacodynamics of centrally acting drugs.

Authors:  J W Mandema; M Danhof
Journal:  Clin Pharmacokinet       Date:  1992-09       Impact factor: 6.447

2.  Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of heptabarbital using aperiodic EEG analysis.

Authors:  J W Mandema; M Danhof
Journal:  J Pharmacokinet Biopharm       Date:  1990-10

3.  Prognostic model for time to achieve independent walking in children with Guillain-Barré syndrome.

Authors:  Peerada Chaweekulrat; Oranee Sanmaneechai
Journal:  Pediatr Res       Date:  2022-02-15       Impact factor: 3.756

4.  Age-dependent stereoselective increase in the oral clearance of hexobarbitone isomers caused by rifampicin.

Authors:  D A Smith; M H Chandler; S I Shedlofsky; P J Wedlund; R A Blouin
Journal:  Br J Clin Pharmacol       Date:  1991-12       Impact factor: 4.335

5.  Disposition of allylic oxidation pathway metabolites of racemic hexobarbital in the rat.

Authors:  M Van der Graaff; N P Vermeulen; M H Vinks; D D Breimer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1986 Apr-Jun       Impact factor: 2.441

6.  Intra-arterial administration of hexobarbital enantiomers to the rat: disposition and estimation of apparent extraction ratio.

Authors:  M Van der Graaff; N P Vermeulen; D D Breimer
Journal:  Pharm Weekbl Sci       Date:  1986-04-25
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.